CTE Company Profile: Directors, Insiders & Operations | Cryosite

CTE

Pharmaceuticals, Biotechnology & Life Sciences

Cryosite

Short interest: 0.00%; as of 23 May 2025
Reported shorts: 634
Shares on issue: 48.810M

Company

AI-generated research profile of Cryosite

pharmaceuticals

biotechnology

clinical trials

logistics

biological storage

Cryosite Ltd is an Australian company specializing in outsourced clinical trials logistics, biological storage, and sample management services. They provide integrated solutions, including the storage of cord blood stem cells for private use, and manage clinical supply chain activities with expertise in temperature-sensitive products.

Director trades

12 trades recorded

Date	Director	Type	Shares	Price	Value
2025-07-01	Unknown Director	buy	-	-	-
2025-06-27	Mark Kerr	buy	75,000	$0.745	$55,873.47
2025-04-10	Unknown Director	buy	-	-	-
2025-04-04	Mark Kerr	buy	231,453	$0.800	$185,131.36
2024-06-25	Mark Kerr	buy	-	-	-
2024-06-25	Andrew Kroger	buy	-	-	-
2024-06-21	Mark Kerr	buy	2,000,000	$1.050	$2,100,000
2024-06-21	Andrew John Kroger	sell	7,000,000	$1.050	$7,350,000
2024-04-26	Mark Kerr	buy	-	-	-
2024-04-26	Andrew Kroger	buy	-	-	-
2024-04-23	Mark Kerr	buy	1,000,000	$0.830	$830,000
2024-04-23	Andrew John Kroger	sell	1,000,000	$0.830	$830,000

CTE intelligence dossier

Public-source evidence for this company, with industry drill-up links.

Tax paid and taxable income records
Government contracts and public money
Emissions and trade exposure
Political donations and lobbying links

Cryosite

Cryosite (CTE) company profile

Profile, insiders and operations

Company

History

Competitive advantages

Risk factors3

Key people8

Director trades

CTE intelligence dossier